Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
Clinical trial NCT05070598 · UNKNOWN
Trial details
- NCT number
- NCT05070598
- Sponsor
- Shengjing Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-07
- Primary completion
- 2023-09-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.